Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of carboplatin + paclitaxel versus induction-based regimens in advanced ovarian carcinoma
2006-000126-31Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Sep 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, paclitaxel and gemcitabine in ovarian cancer and epithelial ovarian cancer (EOC) (3 arms), sponsored by Policlinico Gemelli. Primary endpoint: Objective response rate. Started Sep 2007; status: completed.
02
Drugs
carboplatinpaclitaxelgemcitabine
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2006-000126-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000126-31.